M. S. Jacovides & Co. Ltd
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From M. S. Jacovides & Co. Ltd
Deal Terminations Not The End Of The Road For Licensed Drugs
Post-deal termination, approximately 14% of the drugs from those alliances go on to be approved, and of those still in development, nearly two-thirds advance at least one phase. Third in a series of follow-ups to IN VIVO’s 2014 study comparing/contrasting likelihood of approval and up-front payments on alliances, and the outcomes of relevant deals.
Deals Shaping The Medical Industry, October 2013
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced August through September 2013.
Company Information
- Industry
- Distributors
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice